The GenBody COVID-19 Ag is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal swab specimens from individuals who are suspected of being infected with SARS-CoV-2 by their healthcare provider within the first 6 days of onset of symptoms.
Emergency Use Authorization (EUA) approved.